FinTechFunding

Immutep: Shares positive data from phase 2b AIPAC trial

Immutep Shares positive data from phase 2b AIPAC trial

  • Immutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase IIb AIPAC trial
  • The trial evaluated efti combined with paclitaxel chemotherapy compared to a placebo group in 227 patients with HER2-negative/HR-positive metastatic breast cancer
  • IMM says the higher immune response in efti patients compared to placebo patients confirms efti is activating the immune system and improving overall survival
  • The company is a globally active biotechnology company that is a leader in developing LAG-3 related immunotherapeutic products
  • The company is trading 7.58 per cent higher at 35.5 cents
Previous article
Intigriti: Raises Over €21.13M in Series B Funding
Next article
Elixir Energy: Completes Tim-2 well in Mongolia
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Visa Launches Validator Node on Tempo Blockchain, Strengthening Payments Infrastructure

New validator node aims to boost transaction efficiency for Visa services.Highlights: Visa launches a new validator node on...
FinTech

Amex Launches Agentic Commerce Development Kit to Strengthen Merchant Services

New toolkit aims to enhance payment solutions for businesses.Highlights: Amex unveils Agentic Commerce Development Kit for merchants.The toolkit...
FinTech

Hokodo B2B Buy Now Pay Later App Shuts Down

The closure impacts small businesses utilizing Hokodo’s service.Highlights: Hokodo, the B2B Buy Now Pay Later app, has ceased...
FinTech

Deutsche Börse Invests in Kraken, Strengthening Crypto Market Position

The investment aims to enhance Kraken's offerings and expand market access.Highlights: Deutsche Börse invests in Kraken to boost...